Credit Suisse Reiterates a “Neutral” Rating on Wpp (LON:WPP) and GBX 1300.00 Target; Deerfield Management Company Has Increased Oxford Immunotec Global Plc (OXFD) Position By $4.14 Million

Oxford Immunotec Global PLC (NASDAQ:OXFD) Logo

Credit Suisse currently has a GBX 1300.00 target price on the 14.14 billion GBP market cap company or 16.49% upside potential. In an analyst note made public on Monday, 16 April, Wpp (LON:WPP) stock had its “Neutral” Rating kept by investment analysts at Credit Suisse.

Deerfield Management Company increased Oxford Immunotec Global Plc (OXFD) stake by 33.66% reported in 2017Q4 SEC filing. Deerfield Management Company acquired 318,290 shares as Oxford Immunotec Global Plc (OXFD)’s stock declined 10.21%. The Deerfield Management Company holds 1.26 million shares with $17.66 million value, up from 945,710 last quarter. Oxford Immunotec Global Plc now has $346.43M valuation. The stock increased 1.29% or $0.17 during the last trading session, reaching $13.39. About 98,857 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has declined 19.42% since April 16, 2017 and is downtrending. It has underperformed by 30.97% the S&P500.

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 10 analyst reports since July 19, 2017 according to SRatingsIntel. Robert W. Baird maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) rating on Tuesday, October 31. Robert W. Baird has “Buy” rating and $20.0 target. BTIG Research initiated the stock with “Buy” rating in Thursday, September 28 report. The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) earned “Buy” rating by Cowen & Co on Monday, January 22. Piper Jaffray maintained the shares of OXFD in report on Monday, January 8 with “Buy” rating. The rating was maintained by Cowen & Co on Wednesday, August 16 with “Buy”. On Tuesday, October 31 the stock rating was maintained by Cowen & Co with “Buy”. The rating was maintained by Cowen & Co with “Buy” on Wednesday, July 19. The company was maintained on Wednesday, September 27 by Cowen & Co. Robert W. Baird maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) on Thursday, October 19 with “Buy” rating.

Investors sentiment increased to 1.57 in 2017 Q4. Its up 0.44, from 1.13 in 2017Q3. It increased, as 11 investors sold OXFD shares while 17 reduced holdings. 13 funds opened positions while 31 raised stakes. 23.93 million shares or 6.29% more from 22.51 million shares in 2017Q3 were reported. Parallax Volatility Advisers Lp holds 0% or 3,486 shares. Bancorporation Of America Corporation De owns 3,173 shares for 0% of their portfolio. New Leaf Venture Prns Ltd Llc holds 5.57% or 852,497 shares in its portfolio. Manufacturers Life Insur The holds 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 19,646 shares. Ameritas Investment Inc reported 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Legal And General Public Ltd Co reported 6,491 shares. Bank & Trust Of Ny Mellon Corp, New York-based fund reported 69,740 shares. The California-based Redmile Group Inc Lc has invested 1.41% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Polar Cap Llp stated it has 2.47 million shares or 0.36% of all its holdings. Jefferies Gp Ltd Liability Corp reported 19,511 shares. New York-based New York State Common Retirement Fund has invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Wells Fargo Mn holds 0% or 44,004 shares in its portfolio. Goldman Sachs Grp Inc Incorporated holds 0% or 10,742 shares. Granahan Invest Inc Ma has 0.57% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 515,277 shares. Tiaa Cref Inv Mgmt Ltd owns 85,422 shares for 0% of their portfolio.

Since February 15, 2018, it had 0 insider purchases, and 1 sale for $36,038 activity. 3,000 shares were sold by SANDBERG RICHARD A, worth $36,038 on Thursday, February 15.

Deerfield Management Company decreased Akari Therapeutics Plc stake by 183,766 shares to 249,785 valued at $1.08M in 2017Q4. It also reduced Audentes Therapeutics Inc stake by 334,894 shares and now owns 1.19 million shares. Wave Life Sciences Ltd was reduced too.

WPP plc provides various communications services worldwide. The company has market cap of 14.14 billion GBP. The firm operates through four divisions: Advertising and Media Investment Management; Data Investment Management; Public Relations & Public Affairs; and Branding & Identity, Healthcare and Specialist Communications. It has a 7.84 P/E ratio. The Advertising and Media Investment Management segment provides advertising services; and media planning and buying, and specialist sponsorship, and branded entertainment services.

The stock decreased 5.98% or GBX 71 during the last trading session, reaching GBX 1117. About 4.31 million shares traded. WPP plc (LON:WPP) has 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 25 analysts covering WPP Group PLC (LON:WPP), 14 have Buy rating, 0 Sell and 11 Hold. Therefore 56% are positive. WPP Group PLC has GBX 2250 highest and GBX 1 lowest target. GBX 1615.44’s average target is 44.62% above currents GBX 1117 stock price. WPP Group PLC had 323 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating by Beaufort Securities given on Tuesday, October 27. The firm has “Buy” rating by Liberum Capital given on Wednesday, August 23. On Friday, January 12 the stock rating was maintained by Liberum Capital with “Buy”. The company was maintained on Friday, December 2 by Barclays Capital. The firm has “Overweight” rating given on Thursday, August 27 by JP Morgan. Goldman Sachs downgraded the stock to “Neutral” rating in Tuesday, January 23 report. The stock of WPP plc (LON:WPP) earned “Hold” rating by Liberum Capital on Tuesday, March 8. The stock of WPP plc (LON:WPP) earned “Overweight” rating by Barclays Capital on Tuesday, November 1. The firm has “Neutral” rating given on Wednesday, February 17 by Natixis. The firm earned “Buy” rating on Wednesday, January 10 by Citigroup.

Oxford Immunotec Global PLC (NASDAQ:OXFD) Ratings Chart